What's Happening?
The National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending that the NHS in England and Wales should not continue funding Amgen's lung cancer drug Lumykras (sotorasib). The decision is based on limitations
in clinical evidence and uncertainties in the economic model, which suggest that the drug's cost-effectiveness does not meet the acceptable range for NHS resources. Lumykras, which targets the KRAS G12C mutation in non-small-cell lung cancer (NSCLC), has been available through the Cancer Drugs Fund since 2022. Despite being the first KRAS inhibitor to market, its sales have not met expectations, and NICE's appraisal committee concluded that the benefits of sotorasib were small relative to its costs.
Why It's Important?
NICE's decision to potentially withdraw funding for Lumykras could have significant implications for lung cancer patients in England and Wales, particularly those with the KRAS G12C mutation who have limited treatment options. The move highlights the challenges faced by pharmaceutical companies in demonstrating the cost-effectiveness of new therapies within the NHS framework. For Amgen, the decision represents a setback in its efforts to establish Lumykras as a viable treatment option in the UK market. The outcome also underscores the importance of robust clinical evidence and economic modeling in securing reimbursement for innovative therapies. The decision may prompt other pharmaceutical companies to reassess their strategies for gaining market access in the UK.
What's Next?
Amgen has expressed its intention to continue engaging with NICE, the NHS, clinicians, and patient organizations to explore options for maintaining access to Lumykras for eligible patients. A consultation on the final draft guidance is open until July 23, allowing stakeholders to provide feedback. The outcome of this consultation could influence the final decision on Lumykras's funding status. In the meantime, Amgen may need to consider alternative strategies, such as negotiating price adjustments or providing additional clinical data, to address NICE's concerns. The situation also highlights the need for ongoing dialogue between pharmaceutical companies and health authorities to ensure that patients have access to effective treatments.
